Semi-physiological pharmacokinetic–pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats

References

• Abbott BD, Lau C, Buckalew AR, et al. (1993). Effects of 5-fluorouracil on embryonic rat palate in vitro: fusion in the absence of proliferation. Teratology 47:541–54
   PubMedGoogle Scholar
• Akaike H. (1974). A new look at the statistical model identification. IEEE Trans Automat Contr 19:716–8
   Web of Science ®Google Scholar
• Buchel B, Rhyn P, Schurch S, et al. (2013). LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr 27:7–16
   PubMed Web of Science ®Google Scholar
• Capitain O, Asevoaia A, Boisdron-Celle M, et al. (2008). Influence of pharmacogenetic polymorphisms on 5-fluorouracil and irinotecan efficacy and tolerance in patients treated for advanced colorectal cancer. Proc Am Soc Clin Oncol Gastrointest Cancers Symp Abstract 429
   Google Scholar
• Capitain O, Asevoaia A, Boisdron-Celle M, et al. (2012). Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 11:263–7
   PubMed Web of Science ®Google Scholar
• Cartwright GE, Athens JW, Wintrobe MM. (1964). The kinetics of granulopoiesis in normal man. Blood 24:780–803
   PubMed Web of Science ®Google Scholar
• Catalano V, Bisonni R, Graziano F, et al. (2013). A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer 16:411–19
   PubMed Web of Science ®Google Scholar
• Collins JM, Dedrick RL, King FG, et al. (1980). Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28:235–46
   PubMed Web of Science ®Google Scholar
• Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. (1976). Neutrophil kinetics in man. J Clin Invest 58:705–15
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Lencioni M, Amatori F, et al. (2008). 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res 14:2749–55
   PubMed Web of Science ®Google Scholar
• Filgueiras Mde C, Morrot A, Soares PM, et al. (2013). Effects of 5-fluorouracil in nuclear and cellular morphology, proliferation, cell cycle, apoptosis, cytoskeletal and caveolar distribution in primary cultures of smooth muscle cells. PLoS One 8:e63177
   PubMed Web of Science ®Google Scholar
• Friberg LE, Freijs A, Sandstrom M, Karlsson MO. (2000). Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295:734–40
   PubMed Web of Science ®Google Scholar
• Friberg LE, Henningsson A, Maas H, et al. (2002). Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–21
   PubMed Web of Science ®Google Scholar
• Fuse E, Takai K, Okuno K, Kobayashi S. (1996). Hepatic extraction ratio of 5-fluorouracil in rats. Dose dependence and effect of uracil and interleukin-2. Biochem Pharmacol 52:561–8
   PubMed Web of Science ®Google Scholar
• Gamelin E, Boisdron-Celle M, Delva R, et al. (1998). Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16:1470–8
   PubMed Web of Science ®Google Scholar
• Gamelin E, Delva R, Jacob J, et al. (2008). Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099–105
   PubMed Web of Science ®Google Scholar
• Gamelin E, Capitain O, Morel A, et al. (2009). Comparison of two patient cohorts treated in parallel for advanced colorectal cancer with a simplified FOLFOX 4 regimen with or without 5-FU therapeutic dose management. Proc Am Soc Clin Oncol Gastrointest Cancers Symp Abstract 356
   Google Scholar
• Jarugula VR, Lam SS, Boudinot FD. (1997). Nonlinear pharmacokinetics of 5-fluorouracil in rats. J Pharm Sci 86:756–8
   PubMed Web of Science ®Google Scholar
• Katsube T, Yamano Y, Yano Y. (2008). Pharmacokinetic–pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J Pharm Sci 97:1606–14
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Okada K, et al. (2013a). Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. Biol Pharm Bull 36:907–16
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Okada K, et al. (2013b). Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. J Pharm Sci 102:2056–67
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Kuwano S, Imoto K, et al. (2013c). A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. Biopharm Drug Dispos 34:365–76
   PubMed Web of Science ®Google Scholar
• MacLennan ICM, Drayson MT. (1999). Normal lymphocytes and nonneoplastic lymphocyte disorders. In: Hoffbrand AV, Lewis SM, Tuddenham EGD, eds. Postgraduate haematology, 4th ed. Oxford, United Kingdom: Butterworth–Heinemann, 296
   Google Scholar
• Mager DE, Jusko WJ. (2001). Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210–16
   PubMed Web of Science ®Google Scholar
• Mattison LK, Soong R, Diasio RB. (2002). Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3:485–92
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne MC, Renee N, et al. (1994). Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291–5
   PubMed Web of Science ®Google Scholar
• Naguib FN, el Kouni MH, Cha S. (1985). Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405–12
   PubMed Web of Science ®Google Scholar
• Noguchi C, Miyata H, Sato Y, et al. (2011). Evaluation of bone toxicity in various bones of aged rats. Toxicol Pathol 24:41–8
   Web of Science ®Google Scholar
• Nukatsuka M, Saito H, Sakamoto K, et al. (2012). Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. Anticancer Res 32:2807–12
   PubMed Web of Science ®Google Scholar
• Perlstein I, Stepensky D, Krzyzanski W, Hoffman A. (2002). A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats. J Pharm Sci 91:2500–10
   PubMed Web of Science ®Google Scholar
• Pinedo HM, Peters GF. (1988). Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–64
   PubMed Web of Science ®Google Scholar
• Pratt CB, Meyer WH, Howlett N, et al. (1994). Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Cancer 74:2593–8
   PubMed Web of Science ®Google Scholar
• Quartino AL, Friberg LE, Karlsson MO. (2012). A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs 30:833–45
   PubMed Web of Science ®Google Scholar
• Saif MW, Syrigos K, Mehra R, et al. (2007). Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4-years. Pak J Med Sci 23:832–9
   PubMed Web of Science ®Google Scholar
• Saif MW, Choma A, Salamone SJ, Chu E. (2009). Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543–52
   PubMed Web of Science ®Google Scholar
• Segura C, Bandrés E, Trocóniz IF, et al. (2004). Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res 21:567–73
   PubMed Web of Science ®Google Scholar
• Soto E, Staab A, Tillmann C, et al. (2010). Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 66:785–95
   PubMed Web of Science ®Google Scholar
• Sun YN, Jusko WJ. (1998). Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732–7
   PubMed Web of Science ®Google Scholar
• Sung JH, Dhiman A, Shuler ML. (2009). A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. J Pharm Sci 98:1885–904
   PubMed Web of Science ®Google Scholar
• Syren E. (1974). Turnover of lysozyme-positive monocytes in normal rat blood. Acta Haematol 51:219–26
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Maring JG. (2013). Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics 14:799–811
   PubMed Web of Science ®Google Scholar
• Vincent PC. (1977). The measurement of granulocyte kinetics. Br J Haematol 36:1–4
   PubMed Web of Science ®Google Scholar
• Westermann J, Puskas Z, Pabst R. (1988). Blood transit and recirculation kinetics of lymphocyte subsets in normal rats. Scand J Immunol 28:203–10
   PubMed Web of Science ®Google Scholar
• Yoshikawa R, Kusunoki M, Yanagi H, et al. (2001). Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61:1029–37
   PubMed Web of Science ®Google Scholar
• Zandvliet AS, Schellens JH, Dittrich C, et al. (2008). Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 66:485–97
   PubMed Web of Science ®Google Scholar